Plasma calprotectin is extremely high in patients with lysinuric protein intolerance

dc.contributor.authorKärki, Mari
dc.contributor.authorTanner, Laura
dc.contributor.authorLahtinen, Satu
dc.contributor.authorSoukka, Tero
dc.contributor.authorNiinikoski, Harri
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=biotekniikka|en=Biotechnology|
dc.contributor.organizationfi=lastentautioppi|en=Paediatrics and Adolescent Medicine|
dc.contributor.organization-code1.2.246.10.2458963.20.40612039509
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.contributor.organization-code1.2.246.10.2458963.20.98373201676
dc.converis.publication-id182452658
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/182452658
dc.date.accessioned2025-08-27T12:55:38Z
dc.date.available2025-08-27T12:55:38Z
dc.description.abstract<p>Lysinuric protein intolerance (LPI) is a rare autosomal recessive disorder affecting the transport of cationic amino acids. Elevated plasma zinc concentrations have been described in patients with LPI. Calprotectin is a calcium- and zinc-binding protein, produced by polymorphonuclear leukocytes and monocytes. Both zinc and calprotectin have an important role in immune system. In this study, we describe plasma zinc and plasma calprotectin concentrations in Finnish LPI patients. Plasma calprotectin concentration was measured from 10 LPI patients using an enzyme-linked immunosorbent assay (ELISA) and it was remarkably high in all LPI patients (median: 622 338 μg/L) compared to that in healthy controls (608 μg/L). Plasma zinc concentration was measured by photometry and it was normal or only mildly elevated (median: 14.9 μmol/L). All the patients had decreased glomerular infiltration rate (median: 50 mL/min/1.73 m<sup>2</sup>). In conclusion, we observed extremely high plasma calprotectin concentration in patients with LPI. Mechanism of this phenomenon is unknown.<br></p>
dc.format.pagerange293
dc.format.pagerange299
dc.identifier.jour-issn2192-8304
dc.identifier.olddbid199880
dc.identifier.oldhandle10024/182907
dc.identifier.urihttps://www.utupub.fi/handle/11111/44630
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/full/10.1002/jmd2.12377
dc.identifier.urnURN:NBN:fi-fe2025082784821
dc.language.isoen
dc.okm.affiliatedauthorKärki, Mari
dc.okm.affiliatedauthorLahtinen, Satu
dc.okm.affiliatedauthorSoukka, Tero
dc.okm.affiliatedauthorNiinikoski, Harri
dc.okm.discipline318 Medical biotechnologyen_GB
dc.okm.discipline318 Lääketieteen bioteknologiafi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWiley
dc.publisher.countryGermanyen_GB
dc.publisher.countrySaksafi_FI
dc.publisher.country-codeDE
dc.relation.doi10.1002/jmd2.12377
dc.relation.ispartofjournalJIMD Reports
dc.relation.issue4
dc.relation.volume64
dc.source.identifierhttps://www.utupub.fi/handle/10024/182907
dc.titlePlasma calprotectin is extremely high in patients with lysinuric protein intolerance
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
JIMD Reports - 2023 - Kärki - Plasma calprotectin is extremely high in patients with lysinuric protein intolerance.pdf
Size:
848.16 KB
Format:
Adobe Portable Document Format